Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration

• US 6,200,606 B1
• Filed: 07/14/1997
• Issued: 03/13/2001
• Est. Priority Date: 01/16/1996
• Status: Expired due to Fees

• Current Assignee: DePuy Orthopaedics Incorporated (Johnson & Johnson), Ethicon Incorporated (Johnson & Johnson)
• Original Assignee: DePuy Orthopaedics Incorporated (Johnson & Johnson)
• Inventors: Peterson, Dale R., Nousek-Goebl, Nancy
• Primary Examiner(s): Witz, Jean C.
• Application Number:
  US08/891,952
• Time in Patent Office: 1,338 Days
• Field of Search: 424/93.7, 424/93.71, 424/529, 424/577, 424/574, 435/372
• US Class Current: 424/574
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61L 27/3817 Cartilage-forming cells, e.g. pre-chondrocytes
• CPC Class Codes: A61L 27/3821 Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
• CPC Class Codes: A61L 27/3839 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61L 27/3847 Bones
• CPC Class Codes: A61L 27/3852 Cartilage, e.g. meniscus
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2501/91 Heparin
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Abstract

The present invention relates to the isolation of cartilage or bone precursor cells from hematopoietic and non-hematopoietic cells and their use in bone and cartilage regeneration procedures. The precursor cells are used for in vivo bone or cartilage repair by transplanting the cells, with or without a carrier material and without the need for in vitro culturing of the cells, to sites in the body requiring bone or cartilage repair.

Claims

1. A method for inducing the production of cartilage or bone at a predetermined site in need of repair, said method comprising the step of contacting said site with a composition comprising a population of cells dissociated from adipose tissue said cell population enriched for cells having a density of at least 1.0 g/cm³.

2. The method of claim 1 wherein the enriched cell population is cultured in vitro before contacting the site in need of repair.

3. The method of claim 1 wherein the site in need of repair is contacted with the population of cells by injecting said cells at the site in need of repair.

4. The method of claim 1 wherein the composition further comprises a biocompatible carrier.

5. The method of claim 1 wherein the composition further comprises a carrier selected from the group consisting of demineralized bone matrix, hyaluronate, Collastat®

, polyesters, poly(amino acids), gypsum, fibrin, collagen, and calcium phosphate ceramics.

6. The method of claim 4 wherein the composition further comprises a bioactive compound.

7. A method of promoting the growth of bone or cartilage in a patient at a site in need of repair, said method comprising

surgically implanting a prosthetic device at said site wherein the device comprises cells dissociated from adipose tissue and enriched for cells having a density of at least 1.0 g/cm³.

8. The method of claim 7 wherein the enriched population of cells is generated by centrifugation or gravitational sedimentation of dissociated adipose tissue cells and isolation of cells having a density of at least 1.0 g/cm³.

9. The method of claim 7 wherein the device further comprises a biocompatible carrier and vitronectin.